ALVR
AlloVir (ALVR)
$
84About AlloVir (ALVR)
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Details
Daily high
$0.86
Daily low
$0.80
Price at open
$0.81
52 Week High
$2.48
52 Week Low
$0.58
Market cap
96.9M
Dividend yield
0.00%
Volume
236,558
Avg. volume
190,561
P/E ratio
-.68
AlloVir News
Details
Daily high
$0.86
Daily low
$0.80
Price at open
$0.81
52 Week High
$2.48
52 Week Low
$0.58
Market cap
96.9M
Dividend yield
0.00%
Volume
236,558
Avg. volume
190,561
P/E ratio
-.68